PROCEPT BioRobotics (NASDAQ:PRCT) Director Antal Rohit Desai Buys 167,246 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai purchased 167,246 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, March 5th. The stock was bought at an average price of $25.58 per share, for a total transaction of $4,278,152.68. Following the completion of the transaction, the director directly owned 167,246 shares in the company, valued at $4,278,152.68. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Antal Rohit Desai also recently made the following trade(s):

• On Monday, March 9th, Antal Rohit Desai acquired 98,699 shares of PROCEPT BioRobotics stock. The stock was bought at an average price of $24.55 per share, with a total value of $2,423,060.45.
• On Friday, March 6th, Antal Rohit Desai bought 160,317 shares of PROCEPT BioRobotics stock. The stock was bought at an average cost of $23.59 per share, for a total transaction of $3,781,878.03.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $25.26 on Tuesday. The stock has a market cap of $1.42 billion, a P/E ratio of -14.77 and a beta of 1.03. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The stock’s 50-day moving average price is $29.11 and its two-hundred day moving average price is $32.83. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned ($0.35) earnings per share. On average, equities analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently made changes to their positions in PRCT. Caitong International Asset Management Co. Ltd increased its holdings in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares in the last quarter. JTC Employer Solutions Trustee Ltd bought a new stake in shares of PROCEPT BioRobotics in the third quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter worth about $40,000. Vega Investment Solutions boosted its position in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares during the period. Finally, US Bancorp DE grew its holdings in shares of PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after buying an additional 1,079 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Oppenheimer restated a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Jefferies Financial Group downgraded PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 26th. Robert W. Baird initiated coverage on PROCEPT BioRobotics in a research note on Friday. They issued a “neutral” rating and a $30.00 target price for the company. Finally, Leerink Partners lowered their price target on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $40.82.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.